EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutions

Core Insights - EssilorLuxottica has acquired Ikerian AG, operating under the RetinAI brand, to enhance its capabilities in AI and data management within eyecare [1][2] - The acquisition aims to strengthen the Group's med-tech journey by integrating advanced software that utilizes machine learning and computer vision to improve clinical workflows and patient care [1][3] Company Overview - RetinAI specializes in developing tools for collecting, processing, and grading large-scale retinal images and biomarker datasets, with its flagship platform, RetinAI Discovery, being FDA cleared and CE-marked [2] - The platform supports the diagnosis and monitoring of diseases such as age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy, facilitating timely and accurate decision-making in eye disease management [2] Strategic Goals - The acquisition is part of EssilorLuxottica's broader strategy to create a digitally enabled patient journey, enhancing its ecosystem that includes eyecare, diagnostics, therapeutic innovation, and surgical excellence [3] - The integration of RetinAI's AI-powered analytics is expected to transform clinical data into actionable insights, leading to faster diagnoses and improved disease monitoring [3] Leadership Perspectives - Francesco Milleri, Chairman and CEO of EssilorLuxottica, emphasized the transformative potential of this acquisition for patient care and the healthcare industry as a whole [3] - Carlos Ciller, Chairman and CEO of RetinAI/Ikerian AG, highlighted the opportunity to scale their vision of data and AI-driven patient care through EssilorLuxottica's global reach and commitment to innovation [4]